David Kendall Joins MannKind as Chief Medical Officer
February 06 2018 - 8:00AM
MannKind Corporation (NASDAQ:MNKD) today announced
that David M. Kendall, MD, will join the company as Chief Medical
Officer and assume full responsibility for leading MannKind’s
scientific research, clinical development, regulatory, and medical
affairs activity, effective February 12. Dr. Kendall will report
directly to Michael Castagna, Pharm.D., Chief Executive Officer,
and will join the company's executive leadership team. He will be
based out of MannKind’s Westlake Village, California headquarters.
“David is a world renowned diabetes expert
and represents an important addition to our executive leadership
team,” said Castagna, Chief Executive Officer of MannKind. “His
extensive experience in diabetes research, development, and
clinical care in both U.S. and international markets, will be
instrumental in helping us achieve the growth potential that we
believe Afrezza® clearly possesses.”
Dr. Kendall’s career includes over 30 years of
experience in diabetes and metabolism research, clinical
management, research, and policy advocacy. Most recently, he served
as Research Physician and Vice President of Global Medical Affairs
for Lilly Diabetes, and during that time was responsible for all
medical affairs activities and guided research and development
strategy across multiple geographies. In this role, he worked to
re-establish Lilly Diabetes as a world class medical organization –
and added to his extensive experience with both injected and
mealtime insulins, as well as devices and continuous glucose
monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief
Scientific and Medical Officer at the American Diabetes
Association, where he was responsible for all medical affairs,
medical education, research, outcomes, and medical policy
activities. Earlier in his career, Dr. Kendall served as Medical
Director at the International Diabetes Center, and the Park
Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received
his M.D. and completed his Post Graduate Medical Training at the
University of Minnesota, and earned a B.A. in Biology from St. Olaf
College.
“The research and clinical response to Afrezza
as a mealtime insulin supports ongoing efforts to establish this
product as the standard of care for those living with type 1 or
type 2 diabetes,” said Dr. Kendall. “Afrezza is the only inhaled
fast-acting mealtime insulin on the market, and offers the right
patients a flexible, safe, and effective treatment option. I’m
thrilled to join MannKind, and look forward to being part of a
company that has the potential to transform the lives of so many
people that are living with diabetes.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) inhalation powder, the Company's first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties, including
statements regarding MannKind's ability to directly commercialize
pharmaceutical products. Words such as "believes",
"anticipates", "plans", "expects", "intend", "will", "goal",
"potential" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon MannKind's current expectations. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
risks detailed in MannKind's filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for
the year ended December 31, 2016 and subsequent periodic reports on
Form 10-Q and current reports on Form 8-K. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact Rose Alinaya SVP, Investor
Relations 818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024